Cited by 361Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index, and 2 are not checked yet.

Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

Open access

Gold, Michael, Alderton, Claire, Zvartau-Hind, Marina, Egginton, Sally, Saunders, Ann M., Irizarry, Michael, Craft, Suzanne, Landreth, Gary, Linnamägi, Ülla, Sawchak, Sharon·2010·Dementia and Geriatric Cognitive Disorders

DOI 10.1159/000318845PMC PMC3214882

Open this paper in CoChat — free account

Abstract

Background/Aims: A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer’s disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-Ε4-negative subjects. The current phase III study with prospective stratification by APOE genotype was conducted to confirm the efficacy and safety of RSG XR in mild-to-moderate AD. An open-label extension study assessed the long-term safety and tolerability of 8 mg RSG XR. Methods: This double-blind, randomized, placebo-controlled study enrolled 693 subjects. Within 2 APOE allelic strata (Ε4-positive, Ε4-negative), subjects were randomized (2:2:2:1) to once-daily placebo, 2 mg RSG XR, 8 mg RSG XR or 10 mg donepezil (control). Coprimary endpoints were change from baseline to week 24 in the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog) score, and week 24 Clinician’s Interview-Based Impression of Change plus caregiver input (CIBIC+). Results: At week 24, no significant differences from placebo in change from baseline in coprimary endpoints were detected with either the RSG XR dose in APOE-Ε4-negative subjects or overall. For donepezil, no significant treatment difference was detected in ADAS-Cog; however, a significant difference was detected (p = 0.009) on the CIBIC+. Peripheral edema was the most common adverse event for 8 mg RSG XR (15%) and placebo (5%), and nasopharyngitis for 2 mg RSG XR (7%). Conclusion: No evidence of efficacy of 2 mg or 8 mg RSG XR monotherapy in cognition or global function was detected in the APOE-Ε4-negative or other analysis populations. The safety and tolerability of RSG XR was consistent with its known pharmacology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1159/000318845

Cites

56 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Vascular dementia: Diagnostic criteria for research studies: Report of the NINDS‐AIREN International Workshop*
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Alzheimer’s disease
Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
Development of a Functional Measure for Persons With Alzheimer’s Disease: The Disability Assessment for Dementia
Gélinas, I., Gauthier, L., McIntyre, M., & Gauthier, S. (1999) · American Journal of Occupational Therapy · doi:10.5014/ajot.53.5.471 · Cited by 918
Untitled work
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870

Flagged first, then by citations

Show all 56 references

Sorted by citations

Items 201–300 of 361

New Insights into Microglial Mechanisms of Memory Impairment in Alzheimer’s Disease
Li, N., Deng, M., Hu, G., Li, N., Yuan, H., & Zhou, Y. (2022) · Biomolecules · doi:10.3390/biom12111722 · Cited by 30
Crosstalk between Alzheimer’s disease and diabetes: a focus on anti-diabetic drugs
Goodarzi, G., Tehrani, S. S., Fana, S. E., Moradi‐Sardareh, H., Panahi, G., Maniati, M., & Meshkani, R. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01225-3 · Cited by 29
Advances in the Understanding of the Correlation Between Neuroinflammation and Microglia in Alzheimer’s Disease
Yan, H., Wang, W., Cui, T., Shao, Y., Li, M., Fang, L., & Feng, L. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s455881 · Cited by 32
Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer’s disease
Parsons, C. G., & Rammes, G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1313832 · Cited by 29
Vascular cognitive impairment and dementia: An early career researcher perspective
Silva, N. C. B. S., Bracko, O., Nelson, A. R., de Oliveira, F. F., Robison, L. S., Shaaban, C. E., Hainsworth, A. H., & Price, B. R. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12310 · Cited by 34
Effects of Low Doses of Pioglitazone on Resting-State Functional Connectivity in Conscious Rat Brain
Crenshaw, D. G., Asin, K. E., Gottschalk, W. K., Liang, Z., Zhang, N., & Roses, A. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117973 · Cited by 28
Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease
Lenz, R. A., Pritchett, Y., Berry, S. M., Llano, D. A., Han, S., Berry, D. A., Sadowsky, C., Abi‐Saab, W., & Saltarelli, M. D. (2015) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000093 · Cited by 31
Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective
Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 32
Investigational medications for treatment of patients with Alzheimer disease.
Potter, P. E. (2010) · PubMed · Cited by 27
Drugs targeting APOE4 that regulate beta‐amyloid aggregation in the brain: Therapeutic potential for Alzheimer's disease
Poblano, J., Castillo‐Tobías, I., Berlanga, L., Tamayo‐Ordoñez, M. C., Rodríguez‐Salazar, M. D. C., Silva‐Belmares, S. Y., Aguayo‐Morales, H., & Cobos-Puc, L. E. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.14055 · Cited by 29
New Genes and New Insights from Old Genes
Ringman, J. M., & Coppola, G. (2013) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000429179.21977.a1 · Cited by 27
Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients
Tseng, C. (2019) · Aging · doi:10.18632/aging.101944 · Cited by 25
Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer’s Disease
Adem, M. A., Decourt, B., & Sabbagh, M. N. (2024) · Biomedicines · doi:10.3390/biomedicines12010099 · Cited by 30
The Place of PET to Assess New Therapeutic Effectiveness in Neurodegenerative Diseases
Dupont, A.-C., Largeau, B., Guilloteau, D., Ribeiro, M. J., & Arlicot, N. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/7043578 · Cited by 26
Conquering Insulin Network Dysfunctions in Alzheimer’s Disease: Where Are We Today?
de la Monte, S. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240069 · Cited by 28
Microglia-Mediated Phagocytosis in Alzheimer’s Disease: Mechanisms, Heterogeneity, and Therapeutic Insights
Hassan, H., Rawlinson, C., Lan, Y., Jenkins, S. I., & Chen, R. (2025) · Biomolecules · doi:10.3390/biom15111629 · Cited by 30
Enhancement of select cognitive domains with rosiglitazone implicates dorsal hippocampus circuitry sensitive to PPARγ agonism in an Alzheimer's mouse model
Cortez, I., Hernandez, C. M., & Dineley, K. T. (2020) · Brain and Behavior · doi:10.1002/brb3.1973 · Cited by 23
Mechanisms Involved in Microglial-Interceded Alzheimer’s Disease and Nanocarrier-Based Treatment Approaches
Md, S., Alhakamy, N. A., Alfaleh, M. A., Afzal, O., Altamimi, A. S. A., Iqubal, A., & Shaik, R. A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111116 · Cited by 24
ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis
Staurenghi, E., Leoni, V., Lo Iacono, M., Sottero, B., Testa, G., Giannelli, S., Leonarduzzi, G., & Gamba, P. (2022) · Antioxidants · doi:10.3390/antiox11112168 · Cited by 24
Role of Peripheral and Central Insulin Resistance in Neuropsychiatric Disorders
Alagiakrishnan, K., & Halverson, T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216607 · Cited by 25
Cognitive disorders in diabetic patients
Koekkoek, P. S., Rutten, G. E. H. M., & Biessels, G. J. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53480-4.00011-4 · Cited by 27
Type 3 diabetes (Alzheimer's disease): new insight for promising therapeutic avenues
Candasamy, M., Elhassan, S. A. M., Bhattamisra, S. K., Hua, W. Y., Sern, L. M., Busthamin, N. A. B., Ilni, N. B. M., Shun, N. S., Baohong, L., Ya, N. S., et al. (2020) · Panminerva Medica · doi:10.23736/s0031-0808.20.03879-3 · Cited by 23
Metabolic Profiling of CHO-AβPP695 Cells Revealed Mitochondrial Dysfunction Prior to Amyloid-β Pathology and Potential Therapeutic Effects of Both PPARγ and PPARα Agonisms for Alzheimer's Disease
Chang, K. L., Pee, H. N., TAN, W. P., Dawe, G. S., Holmes, E. C., Nicholson, J. K., Chan, E. C. Y., & Ho, P. C. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-140429 · Cited by 23
Hyperinsulinemia or Insulin Resistance: What Impacts the Progression of Alzheimer’s Disease?
Hegde, V. K., Dhurandhar, N. V., & Reddy, P. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190808 · Cited by 22
Diabesity and Brain Energy Metabolism: The Case of Alzheimer’s Disease
Cardoso, S., Seiça, R. M. F., & Moreira, P. I. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-63260-5_5 · Cited by 24
Exploring Rosiglitazone’s Potential to Treat Alzheimer’s Disease through the Modulation of Brain-Derived Neurotrophic Factor
Nelson, M. L., Pfeifer, J. A., Hickey, J. P., Collins, A. E., & Kalisch, B. E. (2023) · Biology · doi:10.3390/biology12071042 · Cited by 22
Concordance of Several Subcellular Interactions Initiates Alzheimer’s Dementia: Their Reversal Requires Combination Treatment
Fessel, W. J. (2017) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317517698790 · Cited by 21
A Precision Medicine Approach to Treating Alzheimer’s Disease Using Rosiglitazone Therapy: A Biomarker Analysis of the REFLECT Trials
O’Bryant, S. E., Zhang, F., Petersen, M. E., Johnson, L. A., Hall, J. R., & Rissman, R. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201610 · Cited by 21
Sweet memories: 20 years of progress in research on cognitive functioning in diabetes
Biessels, G. J. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.04.055 · Cited by 21
Brain insulin resistance and the therapeutic value of insulin and insulin-sensitizing drugs in Alzheimer’s disease neuropathology
Yang, J. J. (2022) · Acta Neurologica Belgica · doi:10.1007/s13760-022-01907-2 · Cited by 21
Design, synthesis and biological activity evaluation of a new class of 2,4-thiazolidinedione compounds as insulin enhancers
Huiying, Z., Guangying, C., & Zhou, S. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2019.1608197 · Cited by 20
New approaches in psychiatric drug development
van der Doef, T. F., Domingo, S. Z., Jacobs, G. E., Drevets, W. C., Marston, H. M., Nathan, P. J., Tome, M. B., Tamminga, C. A., van Gerven, J., & Kas, M. J. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.06.006 · Cited by 18
Interlink Between Insulin Resistance and Neurodegeneration with an Update on Current Therapeutic Approaches
Bhattamisra, S. K., Shin, L. Y., Saad, H. I. B. M., Rao, V., Candasamy, M., Pandey, M., & Choudhury, H. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200518102130 · Cited by 18
Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies
Kang, J., Ryoo, N., Shin, D. W., Trojanowski, J. Q., & Shaw, L. M. J. (2014) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2014.18.6.447 · Cited by 18
Longitudinal decline in mild‐to‐moderate Alzheimer's disease: Analyses of placebo data from clinical trials
Thomas, R. G., Albert, M., Petersen, R. C., & Aisen, P. S. S. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.01.002 · Cited by 18
Hyperphosphorylation of Tau Protein in Down ’s Dementia and Alzheimer’s Disease: Methylation and Implications in Prevention and Therapy
Nichols, T. W. (2014) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000159 · Cited by 17
Beyond the Obvious: Smoking and Respiratory Infection Implications on Alzheimer's Disease
Wadhwa, R., Paudel, K. R., Mehta, M., Shukla, S. D., Sunkara, K., Prasher, P., Panth, N., Goyal, R., Chellappan, D. K., Gupta, G., et al. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319999200817112427 · Cited by 17
Smart treatment strategies for alleviating tauopathy and neuroinflammation to improve clinical outcome in Alzheimer's disease
Tatiparti, K., Sau, S., Rauf, M. A., & Iyer, A. K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.025 · Cited by 16
Targeting impaired nutrient sensing with repurposed therapeutics to prevent or treat age-related cognitive decline and dementia: A systematic review
Kioussis, B., Tuttle, C. S. L., Heard, D. S., Kennedy, B. K., Lautenschlager, N. T., & Maier, A. B. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101302 · Cited by 19
Glucose-lowering drugs, cognition, and dementia: The clinical evidence
Wu, C., Shapiro, L. R., Ouk, M., MacIntosh, B. J., Black, S. E., Shah, B. R., & Swardfager, W. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104654 · Cited by 20
Neuroprotective effect of naturally occurring RXR agonists isolated from Sophora tonkinensis Gagnep. on amyloid-β-induced cytotoxicity in PC12 cells
Wang, W., Nakashima, K., Hirai, T., & Inoue, M. (2018) · Journal of Natural Medicines · doi:10.1007/s11418-018-1257-z · Cited by 17
Human Glucose Transporters in Health and Selected Neurodegenerative Diseases
Szablewski, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157392 · Cited by 18
Effects of peroxisome proliferator-activated receptor-gamma agonists on cognitive function: a systematic review and meta-analysis
Zhong, H., Geng, R., Zhang, Y., Ding, J., Liu, M., Deng, S., & Tu, Q. (2023) · Biomedicines · doi:10.3390/biomedicines11020246 · Cited by 16
Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta-analysis
Ahuja, M., Siddhpuria, S., Karimi, A., Lewis, K., Wong, E. K. C., Lee, J., Reppas‐Rindlisbacher, C. E., Sood, E., Gabor, C., & Patterson, C. (2023) · Age and Ageing · doi:10.1093/ageing/afad205 · Cited by 15
Therapeutic Potential of Antidiabetic Medications in the Treatment of Cognitive Dysfunction and Dementia
Umegaki, H. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0375-0 · Cited by 17
Global issues in drug development for Alzheimer's disease
Doody, R. S., Cole, P. E., Miller, D. S., Siemers, E., Black, R. S., Feldman, H., Schindler, R. J., Graham, S. M., Heath, T., Khachaturian, A. S., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.01.001 · Cited by 15
Emerging amyloid and tau targeting treatments for Alzheimer’s disease
Khan, A., Corbett, A., & Ballard, C. G. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1326819 · Cited by 16
A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer’s Disease in transgenic mice
Craig, A., Parvez, F., & Issberner, J. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112015 · Cited by 15
Neuroenergetics of traumatic brain injury
Karelina, K., & Weil, Z. M. (2015) · Concussion · doi:10.2217/cnc.15.9 · Cited by 14
Alzheimer’s disease and type 2 diabetes mellitus: similarities in pathomechanisms lead to therapeutic opportunities
Bednarz, K., & Siuda, J. S. (2021) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2021.0056 · Cited by 15
Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial
Burns, J. M., Morris, J. K., Vidoni, E. D., Wilkins, H., Choi, I., Lee, P., Hunt, S. L., Mahnken, J. D., Brooks, W. M., Lepping, R. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70416 · Cited by 17
Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies
Corraliza-Gómez, M., Vargas-Soria, M., & Garcı́a-Alloza, M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00894-1 · Cited by 14
Drug Repositioning of Pioglitazone in Management and Improving the Cognitive Function among the Patients with Mild to Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis
Basutkar, R. S., Sudarsan, P., Robin, S. M., Bhaskar, V., Viswanathan, B., & Ponnusankar, S. (2023) · Neurology India · doi:10.4103/0028-3886.391397 · Cited by 13
Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer’s disease
Lee, H., & Kim, E. Y. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01268-5 · Cited by 14
Correction to: Neuroprotective effect of naturally occurring RXR agonists isolated from Sophora tonkinensis Gagnep. on amyloid-β-induced cytotoxicity in PC12 cells
Wang, W., Nakashima, K., Hirai, T., & Inoue, M. (2019) · Journal of Natural Medicines · doi:10.1007/s11418-019-01305-8 · Cited by 14
An Integrated Molecular Atlas of Alzheimer’s DiseasePreprint
Wörheide, M. A., Krumsiek, J., Nataf, S., Nho, K. T., Greenwood, A. K., Wiley, J. C., Willruth, L.-L., Wu, T., Bellur, O., Marella, B., et al. (2021) · medRxiv · doi:10.1101/2021.09.14.21263565 · Cited by 12
Peroxisome proliferator-activated receptors (PPARs) agonists as promising neurotherapeutics
Ghannam, I. A. Y., Hassan, R. M., & Abdel‐Maksoud, M. S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108226 · Cited by 13
The value of cholinesterase inhibitors for improving neuropsychiatric and functional assessment scores in patients with Alzheimer disease: a systematic review and meta-analysis of on placebo-controlled RCTs
Zhang, Y., Sun, Y., Hu, X., Yao, Y., & Wang, J. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001381 · Cited by 12
Alzheimer disease prevention: Focus on cardiovascular risk, not amyloid?
Geldmacher, D. (2010) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.77gr.2010 · Cited by 12
Brain Lipids in the Pathophysiology and Treatment of Alzheimer’s Disease
Torres, M., Busquets, X., & Escribá, P. V. (2016) · InTech eBooks · doi:10.5772/64757 · Cited by 14
Advancing Nanomaterial-Based Strategies for Alzheimer’s Disease: A Perspective
Zhou, H., Yin, X., Zhang, G., Yang, Z., & Zhou, R. (2025) · JACS Au · doi:10.1021/jacsau.5c00002 · Cited by 15
PhRMA Survey of Pharmacogenomic and Pharmacodynamic Evaluations: What Next?
Grecco, N., Cohen, N., Warner, A. W., López-Correa, C., Truter, S. L., Snapir, A., Piccoli, S. P., Wang, D., Westelinck, A., Hinman, L. M., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.334 · Cited by 11
Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial
Furie, K. L., Viscoli, C. M., Gorman, M., Ford, G. A., Young, L. H., Inzucchi, S. E., Guarino, P., Lovejoy, A. M., CONWIT, R. A., Tanné, D., et al. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316361 · Cited by 11
Cerebral Amyloid Angiopathy and Neuritic Plaque Pathology Correlate with Cognitive Decline in Elderly Non-Demented Individuals
Malek‐Ahmadi, M. H., Chen, K., Perez, S. E., & Mufson, E. J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180765 · Cited by 11
Tackling Alzheimer’s Disease with Existing Drugs: A Promising Strategy for Bypassing Obstacles
Rampa, A., Gobbi, S., Belluti, F., & Bisi, A. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200831140745 · Cited by 11
Are Hippocampal Hypoperfusion and ATP Depletion Prime Movers in the Genesis of Alzheimer’s Disease? A Review of Recent Pertinent Observations from Molecular Biology
Walker, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157328 · Cited by 11
Alzheimer's disease phenotype based upon the carrier status of the apolipoprotein E ɛ4 allele
Ji, X., Peng, X., Tang, H., Pan, H., Wang, W. D., Wu, J., Chen, J., & Wei, N. (2023) · Brain Pathology · doi:10.1111/bpa.13208 · Cited by 9
Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease
Léger, G. C., & Massoud, F. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.811237 · Cited by 10
A PDK-1 allosteric agonist neutralizes insulin signaling derangements and beta-amyloid toxicity in neuronal cells and in vitro
Querfurth, H., Marshall, J., Parang, K., Rioult-Pedotti, M. S., Tiwari, R., Kwon, B., Reisinger, S., & Lee, H.-K. (2022) · PLOS ONE · doi:10.1371/journal.pone.0261696 · Cited by 9
Therapeutic agents for Alzheimer’s disease: a critical appraisal
Weinstock, M. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1484615 · Cited by 9
Pioglitazone attenuates complement-mediated microglial synaptic engulfment in an Alzheimer’s disease model
Zu, J., Li, C., Cui, M., Liu, X., Pan, Z., Li, X., Zhang, F., Gentz, J., Mitteregger-Kretzschmar, G., Herms, J. W., et al. (2025) · Brain · doi:10.1093/brain/awaf462 · Cited by 10
Implications of Successful Symptomatic Treatment in Parkinson’s Disease for Therapeutic Strategies of Alzheimer’s Disease
Zhao, L., Cheng, X., & Zhong, C. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00450 · Cited by 9
Efficacy and safety of hypoglycemic drugs in improving cognitive function in patients with Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis
Wang, X.-C., Chu, C.-L., Li, H.-C., Lu, K., Liu, C.-J., Cai, Y., Quan, S., & Zhang, S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1018027 · Cited by 8
The role of antidiabetic drugs in the treatment of Alzheimer’s disease: systematic review
Ishmuratova, A. N., Abramov, M. A., Олегович, К. К., Ivanyuta, M. V., Shakirova, Z. F., Kitapova, A. I., Usmonov, M., Chernousova, L. M., Valeeva, L. I., Kuznetsova, A. Y., et al. (2023) · Problems of Endocrinology · doi:10.14341/probl13183 · Cited by 9
Diabetic Theory in Anti-Alzheimer’s Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents
Jankowska, A., Wesołowska, A., Pawłowski, M., & Chłoń‐Rzepa, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191011144818 · Cited by 8
Tau, Diabetes and Insulin
Gratuze, M., Joly‐Amado, A., Buée, L., Vieau, D., & Blum, D. L. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9358-8_21 · Cited by 8
Biomarkers for Alzheimer's Disease: Showing the Way or Leading Us Astray?
Quinn, J. F. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129022 · Cited by 8
From a cell's viewpoint: targeting mitochondria in Alzheimer's disease
Carlson, E. A., Rao, V. K., & Yan, S. S. (2013) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2014.04.002 · Cited by 9
Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials
Kennedy, R., Cutter, G., Wang, G., & Schneider, L. S. S. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150847 · Cited by 8
Recent approaches to target apoptosis in neurological disorders
Sodhi, R. K., Grewal, A. K., Madan, J., Singh, T. G., & Kumar, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815762-6.00008-1 · Cited by 7
Foresee Novel Targets for Alzheimer’s Disease by Investigating Repurposed Drugs
Agarwal, K., Katare, D. P., & Jakhmola-Mani, R. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220622162622 · Cited by 7
The Interactions of the 70 kDa Fragment of Cell Adhesion Molecule L1 with Topoisomerase 1, Peroxisome Proliferator-Activated Receptor γ and NADH Dehydrogenase (Ubiquinone) Flavoprotein 2 Are Involved in Gene Expression and Neuronal L1-Dependent Functions
Loers, G., KLEENE, R. B., Bork, U., & Schachner, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032097 · Cited by 7
Risk Factors and Prevention in Alzheimer’s Disease and Dementia
Grande, G., Vetrano, D. L., & Mangialasche, F. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_6 · Cited by 7
Characterization of the Meal-Stimulated Incretin Response and Relationship With Structural Brain Outcomes in Aging and Alzheimer’s Disease
Morris, J. K., John, C. S., Green, Z. D., Wilkins, H., Wang, X., Kamat, A., Swerdlow, R. H., Vidoni, E. D., Petersen, M. E., O’Bryant, S. E., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.608862 · Cited by 5
Role of Oxysterols in the Activation of the NLRP3 Inflammasome as a Potential Pharmacological Approach in Alzheimer's Disease
Martins, G. L., Ferreira, C. N., Palotás, A., Rocha, N. P., & Reis, H. J. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220327215245 · Cited by 6
Effects of rumenic acid rich conjugated linoleic acid supplementation on cognitive function and handgrip performance in older men and women
Jenkins, N. D. M., Housh, T. J., Miramonti, A. A., McKay, B. D., Yeo, N. M., Smith, C. M., Hill, E. C., Cochrane, K. C., & Cramer, J. T. (2016) · Experimental Gerontology · doi:10.1016/j.exger.2016.08.004 · Cited by 6
AlzRiskMR database: an online database for the impact of exposure factors on Alzheimer’s disease
Wang, Z., Meng, L., Liu, H. D., Shen, L., & Ji, H. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa213 · Cited by 6
Diabetes and cognitive dysfunction
Kim, B., Sims‐Robinson, C., Sakowski, S. A., & Feldman, E. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00027-7 · Cited by 8
Microglial Drivers of Alzheimer's Disease Pathology: An Evolution of Diverse Participating States
Kuhn, M. K., & Proctor, E. A. (2024) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26723 · Cited by 5
Molecular mechanisms of exercise-induced improvements in Alzheimer’s disease: a focus on lipid homeostasis
Zhou, J., Zhang, X., Yin, S., Xue, S., He, Q., Chen, S., & Xue, X. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00537-5 · Cited by 5
Lifestyle medicine for healthy cognitive aging: A narrative review
Halma, M. T. J., Marik, P. E., Gazda, S., & Tuszyński, J. A. (2024) · Brain Behavior and Immunity Integrative · doi:10.1016/j.bbii.2024.100077 · Cited by 5
Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes
Arreguín-Cano, J. A., Santana-Delgado, S. A., Villegas‐Mercado, C. E., Orozco-Molina, G. G., Gonzalez-Acosta, A., & Bermúdez, M. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1791782 · Cited by 4
Shared pathophysiology and therapeutic repurposing in Alzheimer's disease and type 2 diabetes: a critical review of convergent mechanisms and clinical challenges
Fu, W., Lu, R., Wang, D., & Sang, Z. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110044 · Cited by 4
PPAR-γ Signaling and Common Protective Pathways against Obesity and Alzheimer's Disease
SHARMA, A. K., Devi, S., Mannan, A., Kumar, M., & Singh, T. G. (2024) · Current Signal Transduction Therapy · doi:10.2174/0115743624267214241016103515 · Cited by 4
Pharmacogenetics in Neurodegenerative Diseases: Implications for Clinical Trials
Tortelli, R., Seripa, D., Panza, F., Solfrizzi, V., & Logroscino, G. (2016) · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences · doi:10.1159/000445453 · Cited by 4
Retracted Article: The interaction between insulin resistance and Alzheimer’s disease: a review article
Albar, N. Y., Hassaballa, H., Shikh, H., Albar, Y., Ibrahim, A. S., Mousa, A. H., Alshanberi, A. M., Elgebaly, A. S., & Bahbah, E. I. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2360887 · Cited by 4
Retracted
The insulin-degrading enzyme: from molecular evolution and subcellular localization to new roles in microglial physiology
Corraliza-Gómez, M. (2021) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/51889 · Cited by 4
E4orf1 improves adipose tissue-specific metabolic risk factors and indicators of cognition function in a mouse model of Alzheimer’s disease
Khan, M. S. H., Hefner, M., Reddy, A. P., Dhurandhar, N. V., & Hegde, V. K. (2023) · Nutrition and Diabetes · doi:10.1038/s41387-023-00242-6 · Cited by 3
Dementia prevention and cardiovascular risk factors: a mini-review
Suemoto, C. K. (2015) · Principles and Practice of Clinical Research Journal · doi:10.21801/ppcrj.2015.11.3 · Cited by 3
Treatment of Dementia: Pharmacological Approaches
Brandt, N., & Mansour, D. Z. (2015) · Springer eBooks · doi:10.1007/978-3-319-18377-0_6 · Cited by 2

Authors: Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S.
Affiliations: GlaxoSmithKline (United Kingdom) (GB)
Duke University (US)
University of Washington (US)
Case Comprehensive Cancer Center (US)
University of Tartu (EE)
ORCID: Alderton, Claire
Saunders, Ann M.
Irizarry, Michael
Craft, Suzanne
Landreth, Gary
Venue: Dementia and Geriatric Cognitive Disorders
Publisher: S. Karger AG
Published: 2010
Volume: 30
Issue: 2
Pages: 131-146
ISSN: 1420-8008 (ISSN-L)
1421-9824
DOI: 10.1159/000318845
PMC: PMC3214882
OpenAlex: W1978999542
Cited by: 361
References: 56
Citations by year: 2026: 12 · 2025: 17 · 2024: 20 · 2023: 21 · 2022: 23 · 2021: 25 · 2020: 26 · 2019: 22 · 2018: 22 · 2017: 19 · 2016: 22 · 2015: 24 · 2014: 24 · 2013: 25 · 2012: 31
FWCI: 18.20
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.karger.com/Services/SiteLicenses (vor)
www.karger.com/Services/SiteLicenses (tdm)
Locations: Dementia and Geriatric Cognitive Disorders (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: GlaxoSmithKline
National Institute on Aging (R01AG030482)
National Institute of Neurological Disorders and Stroke
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, peroxisome proliferator-activated receptor gamma agonists, APOE ε4 genotype, donepezil, cognitive function, global function, peripheral edema, drug safety and tolerability, ADAS-Cog
MeSH terms: Rosiglitazone, Donepezil, Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Apolipoproteins E, Cholinesterase Inhibitors, Edema, Female, Genotype, Humans, Hypoglycemic Agents, Indans, Intelligence Tests, Interview, Psychological, Male, Middle Aged, Nasopharyngitis, Piperidines, Treatment Outcome, Thiazolidinediones, PPAR gamma, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks